drugset / Trial / NCT01776671

Once Daily Gabapentin in the Treatment of Post Amputation Pain

NCT01776671

Phase 3 Unknown 16 enrolled Chicago Anesthesia Pain Specialists
NaSingle-groupOpen-labelTreatment

Summary

Phantom limb pain (PLP) is a common disorder reported by the patients who undergo amputation. Even though the cause of PLP remains unclear, Gabapentin has been widely used. The purpose of this study is to evaluate the accuracy and efficacy achieved in using of extended release Gabapentin. Reducing the incidence of chronic post-amputation pain and improving clinical outcomes postoperatively.

Timeline

Start
2013-02
Primary completion
2018-11
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 1800 mg

Indications

No indication recorded.